These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38745414)

  • 21. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters.
    Lee YG; Chu H; Lu Y; Leamon CP; Srinivasarao M; Putt KS; Low PS
    Nat Commun; 2019 Jun; 10(1):2681. PubMed ID: 31213606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function.
    Lange S; Sand LGL; Bell M; Patil SL; Langfitt D; Gottschalk S
    Cancer Discov; 2021 Jul; 11(7):1661-1671. PubMed ID: 33563660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. γδ T cell-based anticancer immunotherapy: progress and possibilities.
    Meraviglia S; Lo Presti E; Dieli F; Stassi G
    Immunotherapy; 2015; 7(9):949-51. PubMed ID: 26569071
    [No Abstract]   [Full Text] [Related]  

  • 26. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
    Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Nonviral
    Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
    Front Immunol; 2021; 12():802705. PubMed ID: 35082789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
    Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
    Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
    Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
    Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
    Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
    Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
    Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
    Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.
    Thomas P; Paris P; Pecqueur C
    Clin Cancer Res; 2024 Aug; 30(15):3105-3116. PubMed ID: 38747974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer.
    Ajmal I; Farooq MA; Duan Y; Yao J; Gao Y; Hui X; Ge Y; Chen Y; Ren Y; Du B; Jiang W
    Mol Ther; 2024 Oct; 32(10):3539-3557. PubMed ID: 39228124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.